Acquisition Opportunity WCG Clinical acquired Statistics Collaborative in early 2020, creating a potential cross-sell path for WCG’s broader clinical trial and regulatory services to current SCI clients while expanding WCG’s footprint in biostatistical consulting.

Biostatistical Expertise Specialized capabilities in trial design, data monitoring committee reporting, randomization schemes, and FDA presentation consulting position the firm for deeper engagements in cardiovascular, infectious disease, orphan diseases, and vaccines—areas often requiring ongoing statistical support and study design optimization.

Therapeutic Focus Deep experience across cardiovascular, infectious diseases, orphan diseases, and vaccines suggests upsell opportunities with clients pursuing regulatory submissions or post‑marketing commitments that require rigorous statistical analysis, data interpretation, and robust study designs.

Financial Scale Annual revenue in the mid‑single‑digit tens of millions with a lean team of 11–50 employees implies high‑margin, project‑based engagements and potential for expanding consulting services, training, or premium statistical consultation as clients scale.

Digital & Outreach Active web presence and analytics stack including Snowplow, Google Analytics, and SEO tools indicate opportunities to optimize client acquisition channels, content marketing around statistical consulting capabilities, and targeted outreach to biotech and pharma decision makers.